Article Access statistics

Viewed: 675

Emailed: 0

PDF Downloaded: 227

IP Indian Journal of Immunology and Respiratory Medicine


N-Acetyl Cysteine in treatment of COPD


Full Text PDF Share on Facebook Share on Twitter


Author Details : Aleemuddin MM*, Raheem Fatima, Mohsin , Ashfaq Hasan

Volume : 3, Issue : 3, Year : 2018

Article Page : 137-146


Suggest article by email

Abstract

Introduction: In COPD excess expectoration secondary to tracheobronchial secretions contributes to symptoms, airflow obstruction and is diagnostic criterion. It also causes increased mortality, risk of hospitalizations and accelerated decline in FEV1. N-acetylcysteine (NAC) helps in liquefying mucus and DNA (via disruption of disulfide bonds) and has antioxidant effects.
Aims: Evaluate add-on effect of NAC on clinical-physiological parameters in COPD patients treated according to GOLD guidelines.
Material and Methods: Single labeled, randomized, parallel group prospective Observational study. In 120 stable COPD patients Modified medical research council (MMRC) dyspnoea score, COPD Assessment test (CAT score), number of exacerbations and hospitalizations in the last year were recorded and were randomized into 2 groups of 60 each. Group A received NAC 600mg twice daily along with standard treatment. Group B received standard treatment only. Mean and Standard Deviation was compared between groups using unpaired t-test. After 1 year, changes in above parameters were reassessed.
Statistical Analysis: Unpaired t-test and chi square test were used. Statistical significance was set at <0> Results: MMRC score reduced from 3.37 study group) to 2.91, difference being -0.46, and in control from 3.37 to 1.18, difference of -0.22 and p value of p<.05. CAT score reduced more in test group (-4.4) than control group (-3.1), p=.02. Out of 40 exacerbations, 14 (35%) occurred in test and 26 (65%) in control group, reduction of 30% and p=0.01. Out of 28 hospitalizations 10 (36%) test group 18 (64%) control group. i.e. a reduction of 28% and p=0.06.
Conclusions: Use of N-Acetyl Cysteine, 600mg twice daily along with standard treatment can bring clinically significant change in CAT Score and frequency of exacerbations but not in MMRC score and hospitalizations.

Keywords: COPD exacerbation; Hospitalizations; N-Acetyl Cysteine; CAT; MMRC.

Doi : 10.18231/2581-4222.2018.0035

How to cite : Aleemuddin Mm, Fatima R, Mohsin, Hasan A, N-Acetyl Cysteine in treatment of COPD. IP Indian J Immunol Respir Med 2018;3(3):137-146

Copyright © 2018 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)